According to filings with the U.S. Securities and Exchange Commission, Quanta Therapeutics is raising $29,999,993.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Perry Nisen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Quanta Therapeutics
Complex-Directed Therapies to Actively Prevent Resistance. RAS has the highest frequency of mutation of any oncogene in human cancer. Quanta Therapeutics is pioneering allosteric modulation to directly restore conformational control of active RAS signaling at the cell membrane to inhibit the full scope of RAS-driven cancer types. Our team applies deep biologic insight, unique protein conformation detection technology and sophisticated medicinal chemistry expertise to develop novel small molecules as first-in-class precision medicines breaking the resistance paradigms of targeted therapy in oncology.

To learn more about Quanta Therapeutics, visit http://www.quantatx.com/

Contact:
Perry Nisen, Chief Executive Officer
650-799-8230

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.